Complete remission in plasma cell leukaemia.
Two patients with primary plasma cell leukaemia who achieved complete remission are reported. They were treated with induction therapy consisting of a multipeptide derivative of sarcolysin, Peptichemio, given intravenously, combined with vincristine and/or prednisone, followed by conventional melphalan-prednisone therapy. 5-7 months following the beginning of therapy, both patients attained a complete remission which lasted 23 and 6 months; second remission was not achieved. Survival from starting therapy was 57 and 16 months respectively. These cases indicate that intravenous alkylating agents can induce a complete remission in plasma cell leukaemia similar to that achieved in other acute leukaemias.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D010440:Peptichemio / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D010440:Peptichemio; D008558:Melphalan; D011241:Prednisone